Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.
Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.
The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.
Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, reported its Q2 2024 financial results.
Key highlights include total revenues of $413.4M, up 58.1% YoY, and product revenues of $411.4M, up 59.3%. Gross margin improved to 58.8% from 45.2%. The company processed approximately 760,300 tests, a 23.2% increase, including 125,400 oncology tests, a 50.2% increase. Natera achieved a positive cash flow of $3.3M.
Operating expenses rose to $287.1M, driven by headcount growth and increased consulting and legal costs. Net loss narrowed to $37.5M ($0.30/share) from $110.8M ($0.97/share) YoY. Natera's financial outlook for 2024 expects revenues between $1.49B and $1.52B, with a gross margin of 54%-56%.
The company launched a new feature for ProsperaTM Heart and presented new data at the ASCO 2024 Annual Meeting.
Natera, a leader in cell-free DNA testing, announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's leadership team will present on Wednesday, August 14 at 12:30 PM ET in Boston, MA. Investors and interested parties can access a live webcast of the event through Natera's investor relations website. For those unable to attend, a replay will be available shortly after the conference concludes.
This presentation offers an opportunity for investors to gain insights into Natera's current operations, future strategies, and potential growth prospects. As a key player in the cell-free DNA testing market, Natera's participation in this growth-focused conference may signal important developments or expansion plans for the company.
Natera (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results.
Interested parties can access the conference call via the following dial-in numbers:
- Domestic: 1-888-596-4144
- International: 1-646-968-2525
- Conference ID: 7684785
A webcast of the call will be available at https://events.q4inc.com/attendee/455235752, with a replay accessible later at investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) has announced a new study published in the Journal of Clinical Oncology highlighting the utility of its Signatera test for surveillance in Merkel cell carcinoma (MCC). The prospective, multicenter study included 319 patients with stage I-IV MCC. Key findings show that Signatera demonstrated:
- Approximately 95% sensitivity for detecting clinically evident disease at enrollment
- Up to 20 times higher risk of recurrence in ctDNA-positive patients during surveillance
- 91% recurrence-free probability at 12 months for persistently ctDNA-negative patients
The study suggests that Signatera could become a standard monitoring tool in MCC, potentially reducing the frequency of surveillance imaging and guiding treatment decisions.
Natera (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, will present its latest research and data at the 28th International Conference on Prenatal Diagnosis and Therapy. The event, hosted by the International Society of Prenatal Diagnosis (ISPD), will take place from July 7-10, 2024, in Boston, MA. Key presentations include:
1. The evaluation of discordant sex between SNP-based NIPT and prenatal ultrasound related to congenital lipoid adrenal hyperplasia (Presenter: India Bradley, MS, CGC, July 8, 3:30 PM ET).
2. Insights from preimplantation genetic testing on chromosome segregation of human non-homologous Robertsonian translocations (Presenter: Peter Benn, DSc, July 8, 3:30 PM ET).
3. The accuracy of fetal fraction measurement in non-invasive prenatal screening for fetal aneuploidy using SNP-based methodology (Presenter: Peter Benn, DSc, July 9, 10:15 AM ET).
Natera will also host an Industry Symposium on July 9, 2024, at 1:00 PM ET, focusing on the future of non-invasive prenatal testing (NIPT), featuring Medical Directors Samantha Leonard, MBBS, PhD, and Vivienne Souter, MD, MPH.
Sheetal Parmar, Natera's senior vice president of medical affairs for women's health, emphasized the significance of SNP-based NIPT and the company's contributions to preimplantation genetic testing.
Natera (NASDAQ: NTRA) has launched DECIPHER, a Phase II, single-arm trial using its Signatera™ test to guide treatment in gastroesophageal cancer patients. This study, the first to evaluate the HER2-directed antibody-drug conjugate for such patients, aims to enroll 25 participants from over 10 UK sites. Patients showing molecular residual disease (MRD) positivity after neoadjuvant chemotherapy and surgery will receive investigational therapy for up to eight cycles instead of the standard adjuvant chemotherapy. Signatera will monitor MRD clearance, the primary endpoint. Previous data showed high disease progression risk for Signatera-positive patients post-standard treatment. DECIPHER aims to offer these patients a better chance at cure.
Natera (NASDAQ: NTRA) has launched an enhanced version of its Prospera Heart™ test, integrating a Donor Quantity Score (DQS) to better detect heart transplant rejection. Traditional dd-cfDNA tests only measure rejection risk based on the fraction of dd-cfDNA in the blood, potentially skewed by unrelated factors. DQS normalizes these readings, improving the accuracy of rejection detection for both acute cellular rejection (ACR) and antibody-mediated rejection (AMR).
In a study involving 703 plasma samples, the DQS-enhanced Prospera Heart test showed improved performance metrics: sensitivity increased from 80.0% to 88.2%, specificity from 76.1% to 84.2%, and negative predictive value (NPV) from 97.4% to 98.6%. Results were presented at The International Society for Heart and Lung Transplantation’s annual meeting and will be submitted for peer-reviewed publication.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. The presentation is scheduled for 7:40 a.m. PT (10:40 a.m. ET) and can be accessed via a live webcast on Natera's investor relations website. A replay will also be available post-event.
Natera (NASDAQ: NTRA) will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 from June 1–5. The company will showcase 18 abstracts, including results from the ProActive study, the largest prospective dd-cfDNA study in kidney transplant recipients. Key findings highlight the Prospera Kidney test's efficacy in predicting organ rejection, with results demonstrating a high predictive value (AUC range: 92-96%). Additional data show significant variation in dd-cfDNA levels, suggesting its utility in ongoing surveillance and risk stratification for adverse outcomes.
Natera, a global leader in cell-free DNA and genetic testing, will present at the 2024 Leerink Partners Healthcare Crossroads Conference. The presentation is scheduled for Thursday, May 30, 2024, at 8:40 a.m. PT (11:40 a.m. ET). The event will be live-streamed on the investor relations section of Natera's website, with a replay available shortly after.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
What does Natera, Inc. specialize in?
Where is Natera, Inc. headquartered?
What is the Panorama Non-Invasive Prenatal Test (NIPT)?
What is the Horizon Carrier Screening (HCS)?
What is the Signatera Molecular Residual Disease (MRD) Test?
What is the purpose of the Prospera test?
How has Natera advanced genetic testing?
Does Natera offer genetic counseling services?
What industries does Natera serve?
What makes Natera's tests unique?
